Aquatic Capital Management LLC Acquires Shares of 26,418 Galapagos NV (NASDAQ:GLPG)

Aquatic Capital Management LLC purchased a new stake in Galapagos NV (NASDAQ:GLPG - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 26,418 shares of the biotechnology company's stock, valued at approximately $726,000.

Other large investors also recently made changes to their positions in the company. R Squared Ltd acquired a new position in Galapagos in the fourth quarter valued at $26,000. GAMMA Investing LLC increased its stake in shares of Galapagos by 77.4% during the 4th quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company's stock valued at $61,000 after acquiring an additional 974 shares during the last quarter. QRG Capital Management Inc. lifted its holdings in shares of Galapagos by 21.7% during the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock worth $288,000 after acquiring an additional 1,866 shares during the period. XTX Topco Ltd boosted its position in shares of Galapagos by 137.8% in the fourth quarter. XTX Topco Ltd now owns 19,833 shares of the biotechnology company's stock worth $545,000 after acquiring an additional 11,492 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Galapagos by 5.9% in the fourth quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company's stock worth $711,000 after acquiring an additional 1,431 shares during the last quarter. Hedge funds and other institutional investors own 32.46% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. TD Cowen lowered shares of Galapagos from a "strong-buy" rating to a "strong sell" rating in a report on Thursday, January 9th. Morgan Stanley downgraded Galapagos from an "equal weight" rating to an "underweight" rating and lowered their price target for the company from $31.00 to $22.00 in a research report on Friday, February 14th. Barclays restated an "underweight" rating on shares of Galapagos in a report on Thursday, January 23rd. Finally, StockNews.com cut Galapagos from a "hold" rating to a "sell" rating in a report on Friday, April 25th. Five research analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. According to MarketBeat.com, Galapagos currently has an average rating of "Reduce" and a consensus target price of $25.33.

Galapagos Trading Down 0.7 %

Shares of GLPG traded down $0.19 during midday trading on Monday, reaching $27.15. 289,705 shares of the company were exchanged, compared to its average volume of 212,848. Galapagos NV has a 1-year low of $22.36 and a 1-year high of $31.23. The stock has a 50-day moving average price of $25.42 and a 200-day moving average price of $26.07.

Galapagos (NASDAQ:GLPG - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($2.47) EPS for the quarter, missing the consensus estimate of ($0.23) by ($2.24). The company had revenue of $97.33 million during the quarter, compared to analysts' expectations of $72.22 million. Equities analysts forecast that Galapagos NV will post -1.6 earnings per share for the current fiscal year.

Galapagos Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.